Medication info
Glypidin Tablets 2mg (Glimepiride)

Glypidin Tablets 2mg (Glimepiride)

Prescription medicationTabletOral
Ingredient · strength
Glimepiride›2mg / 1 tablet
Manufacturer / importer
CMG Pharmaceutical Co., Ltd.
Appearance
Green rectangular tablet
Packaging
Bottle packaging: 30 tablets, 300 tablets
Approval status
Active

MFDS item code 201403458 · Approved 2014.07.29 · Insurance code 648602700

Summary

Main use
Improvement of glycemic control in type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose should be adjusted individually for each patient. Swallow without chewing with at least 1/2 cup of water. This medicine is taken orally once daily. It should be taken before breakfast or immediately before the first meal. It is very important not to skip a meal after taking this medicine. 1. Monotherapy 1) Initial dose and dose titration In patients who have not previously received drug therapy, initiate treatment with glimepiride 1 mg once daily. If necessary, increase the dose by 1 mg at intervals of 1 ~ 2 weeks. In general, doses above 4 mg provide little additional benefit, although some patients have shown better metabolic control when the dose was increased to 6 mg (or 8 mg). If treatment with 4 mg daily is unsuccessful, first consider switching to insulin therapy; otherwise, consider using insulin or another oral antidiabetic drug in combination. 2) Subsequent dose adjustment As diabetes control improves during treatment, the amount of this medicine required may decrease. Therefore, dose reduction or discontinuation may be necessary to avoid hypoglycemia. Dose adjustment should also be considered if weight loss, lifestyle changes, or other factors that may increase the risk of hypoglycemia or hyperglycemia occur. 3) Switching from another oral hypoglycemic agent to this medicine There is no exact dose equivalence between this medicine and other oral hypoglycemic agents. When switching from another oral hypoglycemic agent to this medicine, it is recommended that the approach described under Initial dose be followed. That is, treatment may be started at 1 mg once daily, with dose adjustment at 1 ~ 2-week intervals. The potency and duration of action of the previous medicine should be taken into consideration. 4) Dose monitoring and adjustment While taking this medicine, blood glucose and/or urine glucose levels should be measured regularly, and regular measurement of glycated hemoglobin (HbA1c) is also recommended. In general, hypoglycemia can be promptly controlled by immediately consuming sugar. Hypoglycemia may recur after initial successful management during treatment with sulfonylureas. Therefore, patients should be monitored carefully. Severe hypoglycemia requires immediate medical treatment and follow-up, and hospitalization is sometimes necessary. 2. Combination therapy 1) Combination therapy with insulin Combination therapy with this medicine and insulin is used in patients with secondary failure, and is used when fasting blood glucose (FBG) exceeds 150 mg/dL. This medicine is given at 8 mg once daily with the first meal, while insulin is started at a low dose and increased at approximately weekly intervals according to fasting blood glucose measurements. Once stabilized, capillary blood glucose should be monitored daily whenever possible. Insulin dose adjustment is required periodically while measuring blood glucose and glycated hemoglobin. 2) Combination therapy with metformin If a patient does not respond adequately to the maximum dose of this medicine, addition of metformin may be considered. Published clinical information is available on combination therapy of metformin with other sulfonylureas, such as glibenclamide, glipizide, chlorpropamide, and tolbutamide. When this medicine is used in combination with metformin, the desired blood glucose level may be achieved by adjusting the dose of each medicine. However, efforts should be made to determine the minimum effective dose of each medicine for blood glucose control. There is a risk of hypoglycemia when this medicine is administered with metformin, and the risk may be increased. Appropriate caution should be exercised.

Ingredients

Manufacturer
CMG Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in type 2 diabetes mellitus

View approved original text

This medication is used to improve blood sugar control in patients with type 2 diabetes. It is effective when taken in conjunction with dietary therapy and exercise for those who find blood sugar control challenging. It can also be administered as a monotherapy, but may be combined with oral hypoglycemic agents or insulin as needed. It is helpful for blood sugar control when used alongside metformin in patients who have insufficient response to sulfonylureas or metformin as monotherapy. This medication plays an important role in managing type 2 diabetes and improves blood sugar control.

How to take

Adult dose

The dose should be adjusted individually for each patient. Swallow without chewing with at least 1/2 cup of water. This medicine is taken orally once daily. It should be taken before breakfast or immediately before the first meal. It is very important not to skip a meal after taking this medicine. 1. Monotherapy 1) Initial dose and dose titration In patients who have not previously received drug therapy, initiate treatment with glimepiride 1 mg once daily. If necessary, increase the dose by 1 mg at intervals of 1 ~ 2 weeks. In general, doses above 4 mg provide little additional benefit, although some patients have shown better metabolic control when the dose was increased to 6 mg (or 8 mg). If treatment with 4 mg daily is unsuccessful, first consider switching to insulin therapy; otherwise, consider using insulin or another oral antidiabetic drug in combination. 2) Subsequent dose adjustment As diabetes control improves during treatment, the amount of this medicine required may decrease. Therefore, dose reduction or discontinuation may be necessary to avoid hypoglycemia. Dose adjustment should also be considered if weight loss, lifestyle changes, or other factors that may increase the risk of hypoglycemia or hyperglycemia occur. 3) Switching from another oral hypoglycemic agent to this medicine There is no exact dose equivalence between this medicine and other oral hypoglycemic agents. When switching from another oral hypoglycemic agent to this medicine, it is recommended that the approach described under Initial dose be followed. That is, treatment may be started at 1 mg once daily, with dose adjustment at 1 ~ 2-week intervals. The potency and duration of action of the previous medicine should be taken into consideration. 4) Dose monitoring and adjustment While taking this medicine, blood glucose and/or urine glucose levels should be measured regularly, and regular measurement of glycated hemoglobin (HbA1c) is also recommended. In general, hypoglycemia can be promptly controlled by immediately consuming sugar. Hypoglycemia may recur after initial successful management during treatment with sulfonylureas. Therefore, patients should be monitored carefully. Severe hypoglycemia requires immediate medical treatment and follow-up, and hospitalization is sometimes necessary. 2. Combination therapy 1) Combination therapy with insulin Combination therapy with this medicine and insulin is used in patients with secondary failure, and is used when fasting blood glucose (FBG) exceeds 150 mg/dL. This medicine is given at 8 mg once daily with the first meal, while insulin is started at a low dose and increased at approximately weekly intervals according to fasting blood glucose measurements. Once stabilized, capillary blood glucose should be monitored daily whenever possible. Insulin dose adjustment is required periodically while measuring blood glucose and glycated hemoglobin. 2) Combination therapy with metformin If a patient does not respond adequately to the maximum dose of this medicine, addition of metformin may be considered. Published clinical information is available on combination therapy of metformin with other sulfonylureas, such as glibenclamide, glipizide, chlorpropamide, and tolbutamide. When this medicine is used in combination with metformin, the desired blood glucose level may be achieved by adjusting the dose of each medicine. However, efforts should be made to determine the minimum effective dose of each medicine for blood glucose control. There is a risk of hypoglycemia when this medicine is administered with metformin, and the risk may be increased. Appropriate caution should be exercised.

Precautions

This medication should not be used in patients with insulin-dependent diabetes, diabetic ketoacidosis, or in a coma. Additionally, patients who have had an allergic reaction to this medication, its ingredients, or sulfonylureas should not be given this medication. There is no experience in using this medication in patients with severe liver or kidney dysfunction, and it is recommended to switch to insulin therapy for these patients. Women who are pregnant or may become pregnant, as well as nursing mothers, should also avoid taking this medication. For patients with severe infections, before and after surgery, or severe trauma, insulin therapy is more suitable than this medication. In cases of gastrointestinal disturbances such as diarrhea or vomiting, caution must be taken as improper food absorption may increase the risk of hypoglycemia. This medication contains lactose, so it should not be given to patients with lactose intolerance or certain genetic metabolic disorders. During the first week of administration, the risk of hypoglycemia is high, so blood sugar should be monitored very closely. Patients with poor nutritional status, irregular eating habits, skipping meals, excessive exercise, and imbalanced carbohydrate intake are also at increased risk for hypoglycemia. Patients consuming alcohol or with decreased kidney and liver function, as well as those who overdose on this medication, may also have an increased risk of hypoglycemia. Elderly patients or those with endocrine disorders, as well as those taking multiple medications, should also be careful. Use with caution in patients with an allergy to Yellow 4 (tartrazine) present in this medication. Symptoms of hypoglycemia can vary and may include headache, severe hunger, nausea, fatigue, anxiety, confusion, drowsiness, loss of consciousness, etc. In severe cases, this can lead to seizures or coma, so immediate action must be taken upon symptom onset. Various side effects such as blurred vision, gastrointestinal disturbances, liver dysfunction, hematologic abnormalities, and allergic reactions may occur, so report any unusual symptoms to a doctor or pharmacist. This medication is effective when taken with regular dosing, along with dietary therapy, exercise therapy, and weight management. In the event of hypoglycemia, be prepared to consume sugar-containing foods to raise blood sugar levels immediately. When receiving treatment at another hospital or pharmacy, be sure to inform them that you are currently taking this medication, and insulin therapy may need to be initiated during stressful situations or surgeries. This medication is excreted through the kidneys, so dosage adjustment is necessary in elderly patients or those with diminished kidney function. In the case of overdose, emergency measures like inducing vomiting, blocking absorption of the drug, and administering glucose injection may be necessary, and if symptoms of hypoglycemia are severe, immediate hospitalization is required. This medication has not established safety or efficacy in children, so it will not be used.

Side effects

Hypoglycemia, headache, severe hunger, nausea, vomiting, fatigue, sleep, sleep disorders, anxiety, aggression, decreased concentration, decreased agility or activity, depression, confusion, speech abnormalities, aphasia, visual disturbances, tremors, partial paralysis, sensory disturbances, dizziness, lethargy, loss of self-control, temporary mental confusion, cerebral convulsions, drowsiness, loss of consciousness, coma, shallow breathing, bradycardia, sweating, cold and clammy skin, tachycardia, hypertension, palpitations, angina, deep vein thrombosis, blurred vision, feeling of fullness or pressure in the upper abdomen, abdominal pain, diarrhea, increased liver enzymes, liver dysfunction, bile secretion disorders, jaundice, hepatitis, thrombocytopenia, leukopenia, hemolytic anemia, erythrocytopenia, granulocytopenia, agranulocytosis, pancytopenia, itching, hives, rash, respiratory distress, hypotension, shock, anaphylaxis, angioedema, Stevens-Johnson syndrome, allergic vasculitis, photosensitivity reactions of the skin, decreased serum sodium concentration, taste disorders, hair loss, weight gain, dizziness, liver dysfunction, abdominal pain, arthralgia, dyspepsia, facial edema, erectile dysfunction, flushing, gastritis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to protect it from exposure to air or moisture. Also, it is important to store it at a temperature between 1 and 30 degrees Celsius to maintain its effectiveness.

Appearance and packaging

Appearance

Green rectangular tablet

Package unit

Bottle packaging: 30 tablets, 300 tablets

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.